Publication:
Heterotopic transplantation of total face/scalp flap

dc.contributor.coauthorDemir, Yavuz
dc.contributor.departmentSchool of Medicine
dc.contributor.facultymemberYes
dc.contributor.kuauthorÖzmen, Selahattin
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T22:50:04Z
dc.date.issued2015
dc.description.abstractThere are various conventional techniques for the reconstruction of the face and scalp region following severe face and scalp deformities caused by extensive tumor ablation, thermal or chemical burns or mechanical trauma. Traditional reconstructive alternatives include skin grafts, local flaps, free-tissue transfers, and prefabricated flaps used in combination with tissue expansion techniques. Despite the use of meticulous techniques and artistic creativity, full functional and aesthetic reconstruction is challenging and can rarely be achieved. When the autogenous tissues are not available or not good enough for the reconstruction of the face and scalp region, allogeneic tissues or organs from cadaveric sources may serve as a reconstructive option. But there may a risk of acute or subacute rejection which may be catastrophic. In an attempt to mimic the clinical scenario of a babysitter procedure we developed an experimental model of the heterotopic total face/scalp transplantation model in rats. A total of 32 animals were studied in three experimental groups. In groups I and II non-vascularized isogeneic and allogeneic total heterotopic face/scalp flap transplantations were performed. In group III vascularized allogeneic total heterotopic face/scalp flap transplantation was accomplished. To prevent acute and chronic allograft rejection, Cyclosporine-A (16 mg/kg per day) therapy was initiated 24 h after transplantation in the allotransplantation groups and the dose was tapered to 2 mg/kg per day within 4 weeks and was maintained at that level thereafter. In the control group with non-vascularized transplants (group I and II), flap necrosis within 5–7 days after transplantation was observed in all transplants. Long-term survival (>400 days) was achieved, without any signs of rejection, with low-dose (2 mg/kg per day) cyclosporine A therapy in group III. This is the first report documenting successful heterotopic composite total face/scalp flap allotransplantation in the rat model.
dc.description.indexedbyScopus
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.studentonlypublicationNo
dc.description.studentpublicationNo
dc.identifier.WoSQuartileN/A
dc.identifier.doi10.1007/978-1-4471-6335-0_41
dc.identifier.endpage340
dc.identifier.isbn9781447163350
dc.identifier.isbn9781447163343
dc.identifier.scopus2-s2.0-84948083356
dc.identifier.startpage331
dc.identifier.urihttps://doi.org/10.1007/978-1-4471-6335-0_41
dc.identifier.urihttps://hdl.handle.net/20.500.14288/6599
dc.keywordsAllotransplantation
dc.keywordsComposite tissue allotransplantation
dc.keywordsFace
dc.keywordsHeterotopic
dc.keywordsScalp
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofPlastic and Reconstructive Surgery: Experimental Models and Research Designs
dc.subjectComposite tissue allotransplantation
dc.subjectFacial transplantation
dc.subjectReconstructive surgery
dc.subjectTransplant immunology
dc.titleHeterotopic transplantation of total face/scalp flap
dc.typeBook Chapter
dspace.entity.typePublication
local.contributor.kuauthorÖzmen, Selahattin
relation.isGoalOfPublicationa9786601-9431-4553-9a46-013bb366fb87
relation.isGoalOfPublication.latestForDiscoverya9786601-9431-4553-9a46-013bb366fb87
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files